Specifically, molecular therapies aimed at human epidermal growth factor receptor-2 (HER2) and vascular endothelial growth factor receptor (VEGFR) have garnered considerable attention within gastric cancer treatment and have successfully been applied in clinical settings (6, 7). Here, ERBB2 is linked to gastric cancer.